N-methyl-5,6-diphenyl-1,2,4-triazin-3-amine | 115125-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: N-methyl-5,6-diphenyl-1,2,4-triazin-3-amine
• CAS: 115125-14-9
• 化学式: C₁₆H₁₄N₄
• 分子量: 262.314
• InChiKey: LHWJYXONBAEPKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-methyl-5,6-diphenyl-1,2,4-triazin-3-amine 、 碘甲烷 以62%的产率得到
  参考文献：
  名称：

  JACOBSEN, NOEL W.;JONGE, IAN DE, AUSTRAL. J. CHEM., 40,(1987) N 12, 1979-88

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氯-5,6-二苯基-1,2,4-三嗪 、 甲胺 以 水 为溶剂， 反应 4.0h， 以66%的产率得到N-methyl-5,6-diphenyl-1,2,4-triazin-3-amine
  参考文献：
  名称：

  Jacobsen, Noel W.; Jonge, Ian de, Australian Journal of Chemistry, 1987, vol. 40, # 12, p. 1979 - 1988

  摘要：

  DOI：

文献信息

• [EN] 1,2,4-TRIAZINE-4-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZINE-4-AMINE
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2011095625A1

  公开（公告）日：2011-08-11

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.

  根据该发明提供了一种A1式化合物，可能对通过抑制A1-A2b或特别是A2a受体而得到改善的疾病或紊乱治疗有用，其中A1式化合物具有以下结构，其中，A代表Cy1或HetA；Cy1代表一个由一个、两个或三个环组成的5-至14-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy1基团可选择地被一个或多个R4a取代基所取代；HetA代表一个由一个、两个或三个环组成的5-至14-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个、两个或三个环，且该HetA基团可选择地被一个或多个R4b取代基所取代；B代表Cy2或HetB；Cy2代表一个由一个或两个环组成的3-至10-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy2基团可选择地被一个或多个R4c取代基所取代；HetB代表一个由一个或两个环组成的3-至10-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个或两个环，且该HetB基团可选择地被一个或多个R4d取代基所取代。
• 1,2,4-TRIAZINE-4-AMINE DERIVATIVES
  申请人：Congreve Miles Stuart

  公开号：US20130029963A1

  公开（公告）日：2013-01-31

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.

  根据本发明提供了一种A1式化合物，该化合物可能有用于治疗通过抑制A1-A2bor，特别是A2a受体而改善的疾病或疾病状态，其中A1式化合物具有以下结构，其中A代表Cy1或HetA；Cy1代表一个5到14个成员的芳香族、完全饱和或部分不饱和的碳环状环系，包括一个、两个或三个环，该Cy1基团可以被一个或多个R4a取代；HetA代表一个5到14个成员的杂环基团，可能是芳香族、完全饱和或部分不饱和的，并且其中包含一个或多个从O、S和N中选择的杂原子，该杂环基团可以包括一个、两个或三个环，该HetA基团可以被一个或多个R4b取代；B代表Cy2或HetB；Cy2代表一个3到10个成员的芳香族、完全饱和或部分不饱和的碳环状环系，包括一个或两个环，该Cy2基团可以被一个或多个R4c取代；HetB代表一个3到10个成员的杂环基团，可能是芳香族、完全饱和或部分不饱和的，并且其中包含一个或多个从O、S和N中选择的杂原子，该杂环基团可以包括一个或两个环，该HetB基团可以被一个或多个R4d取代。
• 1,2,4-triazine-4-amine derivatives
  申请人：Heptares Therapeutics Limited

  公开号：US10112923B2

  公开（公告）日：2018-10-30

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.

  根据本发明，提供了一种式 A1 的化合物，该化合物可用于治疗通过抑制 A1-A2b 或特别是 A2a 受体而改善的病症或紊乱，其中式 A1 的化合物具有如下结构，其中，A 代表 Cy1 或 HetA；Cy1 代表由一个、两个或三个环组成的 5 至 14 元芳香族、完全饱和或部分不饱和碳环系统，该 Cy1 基团任选被一个或多个 R4a 取代基取代；HetA 代表 5 至 14 元杂环基团，可以是芳香族、完全饱和或部分不饱和的杂环基团，含有一个或多个选自 O、S 和 N 的杂原子，该杂环基团可以包括一个、两个或三个环，该 HetA 基团任选被一个或多个 R4b 取代基取代；B 代表 Cy2 或 HetB；Cy2 代表由一个或两个环组成的 3 至 10 元芳香族、完全饱和或 部分不饱和碳环系统，其 Cy2 基团可任选被一个或多个 R4c 取代基取代；HetB 代表 3 至 10 元杂环基团，可以是芳香族、完全饱和或部分不饱和的杂环基团，其中含有一个或多个选自 O、S 和 N 的杂原子，该杂环基团可包括一个或两个环，该 HetB 基团可任选被一个或多个 R4d 取代基取代。
• JACOBSEN, NOEL W.;JONGE, IAN DE, AUSTRAL. J. CHEM., 40,(1987) N 12, 1979-88
  作者：JACOBSEN, NOEL W.、JONGE, IAN DE

  DOI：——

  日期：——
• US8809525B2
  申请人：——

  公开号：US8809525B2

  公开（公告）日：2014-08-19